HANSOH Aktie

 

Goldman Sachs issued a research report stating that HANSOH PHARMA (03692.HK) announced a strategic collaboration and licensing agreement with Roche covering two preclinical ADC projects, as well as multiple additional projects based on targets proposed by Roche and leveraging Hansoh's proprietary ADC technology platform. The dea......

Nomura published a research report stating that HANSOH PHARMA (03692.HK) reached a landmark collaboration agreement with Roche covering a series of antibody-drug conjugate (ADC) projects, including two of Hansoh's preclinical ADC projects and multiple ADC projects proposed by Roche and developed based on Hansoh's proprietary ADC......

HANSOH PHARMA (03692.HK) opened 2.71% higher today and once peaked at HKD34.38. It is now trading at HKD33.76, up 6.36%, with turnover of 11.3979 million shares, involving HKD386 million.The group announced that its wholly owned subsidiaries Shanghai Hansoh Biomedical Technology, Changzhou Hengbang Pharmaceutical and Hansoh Bio,......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials....

Pharma - Der Pharmakonzern Roche ist mit dem chinesischen Unternehmen Hansoh Pharmaceutical Group erneut eine strategische Partnerschaft eingegangen....

Pharma - Der Pharmakonzern Roche ist mit dem chinesischen Unternehmen Hansoh Pharmaceutical Group erneut eine strategische Partnerschaft eingegangen....

HKEX (00388.HK) announced that it will add 12 single stock option classes on November 9, covering KINGBOARD HLDG (00148.HK), ASMPT (00522.HK), KB LAMINATES (01888.HK), CHINAGOLDINTL (02099.HK), CSOP HS TECH (03033.HK), HANSOH PHARMA (03692.HK), GIGADEVICE (03986.HK), BIREN TECH (06082.HK), CIG (06166.HK), MONTAGE TECH (06809.HK)......

19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt...

19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh’s Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD...

MILAN, Oct. 2, 2026 /PRNewswire/ -- From September 28 to October 2, 2026, the Annual Meeting of the European Association for the Study of Diabetes (EASD) is being held in Milan, Italy. Hansoh Pharma's self-developed dual-biased glucagon-like peptide-1/glucose-dependent insulinotropic......

HSBC Global Investment Research issued a research report stating that amid anti-corruption measures and medical insurance cost controls, China's pharmaceutical companies delivered mixed results in 1H26. Share prices of the pharma companies covered by the broker corrected by an average of about 19% YTD, significantly underperform......

Despite mounting US interest rates, China's biopharmaceutical sector remained resilient in late September across the Hong Kong and mainland China markets, supported by policy measures and prospects for out-licensing, HSBC Global Investment Research said in a report.2026 will be a harvest year for China's innovative drug ......

HANSOH PHARMA (03692.HK) announced that, based on positive results from the pivotal Phase III ARTEMIS-011 trial of HS-20093 for injection (rilvegostomig antibody for injection), the indication for treating osteosarcoma patients aged 12 or above who have failed at least second-line prior therapies has been included in the Nationa......

Das Instrument 3KY KYG549581067 HANSOH PHARMAC. HD-,00001 EQUITY wird cum Dividende/Zinsen gehandelt am 21.09.2026 und ex Dividende/Zinsen am 22.09.2026 The instrument 3KY KYG549581067 HANSOH PHARMAC. HD-,00001 EQUITY has its pre-dividend/interest day on 21.09.2026 and its ex-dividend/interest day on 22.09.2026...

HANSOH PHARMA (03692.HK) announced that HS-20197 for injection, a Category 1 innovative drug independently developed by the group, has received a Clinical Trial Approval Notice issued by the National Medical Products Administration of China. The drug is intended for clinical trials targeting advanced solid tumors. (sl/ad)~AASTOC......

G Sachs released a report stating that HANSOH PHARMA (03692.HK) recently announced data from the China Phase III study of B7-H3-targeted antibody-drug conjugate (ADC) Ris-Rez, demonstrating statistically significant and clinically meaningful overall survival (OS) benefits in the treatment of relapsed small cell lung cancer (SCLC......

UBS published a report stating that HANSOH PHARMA (03692.HK)'s B7-H3-targeting antibody-drug conjugate (ADC) Ris-Rez achieved positive results in a Phase III study for treating relapsed small cell lung cancer (SCLC), with improvements in survival and tumor control, alongside fewer treatment-related adverse events, demonstrating ......

JPM released a report stating that HANSOH PHARMA (03692.HK)'s internally developed B7-H3-targeting antibody-drug conjugate (ADC) Ris-Rez recently announced updated study data, showing positive overall survival (OS) results in the treatment of second-line relapsed small cell lung cancer (2L SCLC). Its efficacy was comparable to T......